The Business Research Company’s Next-Generation Antibody Therapeutics Global Market Report 2023 is the most detailed report available on the market, including broad forecast periods and multiple geographies. The report covers the historic period – 2010-2021, and the forecast period – 2023-2032. The Next-Generation Antibody Therapeutics Global Market Report 2023 evaluates next-generation antibody therapeutics market size, growth rate, drivers, trends, and major companies.

The report provides a global perspective by covering 60 geographies and focusing on major economies in each region – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample_request?id=12678&type=smp

The global next-generation antibody therapeutics market is expected to grow from $5.44 billion in 2022 to $6.14 billion in 2023 at a compound annual growth rate (CAGR) of 12.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and resulted in increased interest rates affecting many markets across the globe. The next-generation antibody therapeutics market is expected to reach $9.43 billion in 2027 at a CAGR of 11.3%.

The increasing prevalence of chronic diseases is expected to propel the growth of the next-generation antibody therapeutics market going forward. Chronic diseases are problems that last a year or longer, necessitating continuing medical care, restricting everyday activities, or both. Next-generation antibody therapeutics have a therapeutic function for individuals with chronic illnesses that deliver more focused care, which would benefit patients’ outcomes. For instance, in January 2023, according to the National Center for Biotechnology Information (NCBI), a US-based National Library of Medicine, it was projected that by the year 2050, the number of individuals aged 50 years and older who have at least one chronic illness will surge by 99.5%, rising from 71.522 million in 2020 to 142.66 million. Therefore, the increasing prevalence of chronic diseases is driving the growth of the next-generation antibody therapeutics market.

Get More Information On The Next-Generation Antibody Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/next-generation-antibody-therapeutics-global-market-report

The next-generation antibody therapeutics market segments in the report are:

1) By Types Of Antibodies: Monoclonal Antibodies, Polyclonal Antibodies, Biospecific Antibodies, Antibody-Drug Conjugates, Other Types

2) By Therapeutic Area: Oncology, Autoimmune Diseases, Infectious Diseases, Neurodegenerative Disorders, Other Therapeutic Areas

3) By End-User: Hospitals And Clinics, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End-Users

The table of contents in TBRC’s next-generation antibody therapeutics market report includes:

Executive Summary
Next-Generation Antibody Therapeutics Market Characteristics
Next-Generation Antibody Therapeutics Market Trends And Strategies
Next-Generation Antibody Therapeutics Market - Macro Economic Scenario
Next-Generation Antibody Therapeutics Market Segmentation
.

.

.

Global Next-Generation Antibody Therapeutics Market Competitive Benchmarking
Global Next-Generation Antibody Therapeutics Market Competitive Dashboard
Key Mergers And Acquisitions In The Next-Generation Antibody Therapeutics Market
Next-Generation Antibody Therapeutics Market Future Outlook and Potential Analysis
Appendix
Learn About Us:

The Business Research Company is a market intelligence firm that pioneers in market, company, and consumer research. TBRC’s specialist consultants are located globally and are experts in a wide range of industries that include healthcare, manufacturing, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293



Email: [email protected]



Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model